2012
Sirona gains despite flat profits
Sirona Dental Systems (NSDQ:SIRO) reported flat profits for its fiscal 1st quarter, but that didn’t faze investors, who sent share prices up nearly 4% this week.
Hospira lowers 2013 forecast after FDA bans more infusion pump imports
Stryker hits a 52-week high | Wall Street Beat
Shares of Stryker (NYSE:SYK) hit a 52-week high yesterday, peaking at $64.46 apeice before closing at $63.88, down 0.2% on the day.
STK shares are up about 3% since the medical device company reported 4th-quarter and 2012 results Jan. 24. Stryker said yesteday that it plans to issue a 26.5¢ dividend to shareholders.
Invacare ekes out 2012 profit, despite ‘most challenging year’
Palomar Medical gains on swing to Q4 black
Palomar Medical (NSDQ:PMTI) gained on Wall Street today after a swing to 4th-quarter profits bested Wall Street’s earnings expectations by 1 thin dime.
Surgical devices: Misonix swings to the red in Q2
Conceptus hits 52-week high on swing to Q4, 2012 black
CareFusion’s Q2 sales, earnings rise
CareFusion (NYSE:CFN) maintained its sales outlook for the rest of fiscal 2013 after reporting sales and profit growth for its 2nd quarter.
The healthcare giant posted profits of $108 million, or 48¢ per share, on sales of $909 million for the 3 months ended Dec. 31, 2012, for profit growth of 13.7% on a top-line gain of 2.1%.
Losses soar, shares plummet for Accuray
Accuray (NSDQ:ARAY) shares lost nearly 10% today after the medical device company reported soaring losses and a nearly 27% sales slide for its fiscal 2nd quarter.
The Sunnyvale, Calif.-based company, which makes radiation oncology equipment, posted losses of $29.2 million, or 40¢ per share, on sales of $77.8 million for the 3 months ended Dec. 31, 2012. That amounts to a 180.8% increase in losses and a 26.9% top-line reduction.
Smith & Nephew’s Q4 profits down, 2012 profits flat
Smith & Nephew (FTSE:SN, NYSE:SNN) shares are up slightly in The City and down a tick on The Street, after the British orthopedics giant reported flat profits for 2012 and a slight decline for the 4th quarter, excluding 1-time costs from acquisitions and restructuring.